In addition to its diagnostic utility for AD, NfL can be used as a screening biomarker of early neurodegeneration to predict the risk of dementia onset in the vulnerable population, as well as a prognostic biomarker of downstream neurodegenerative changes to identify cognitively impaired individuals who are likely to progress further along the trajectory of cognitive impairment. This evidence concerns the gene NEFL and Alzheimer disease.